Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

This open-label, multicenter trial will evaluate the efficacy and safety of treatment with AMN107 in chronic myelogenous leukemia (CML) patients that are resistant and/or intolerant to imatinib mesylate therapy.

Inclusion Criteria:

• Imatinib - resistant or - intolerant Philadelphia chromosome-positive CML in blast crisis, accelerated or chronic phase
• Males or females ≥ 18 years of age

Exclusion Criteria:

• Impaired cardiac function
• Acute or chronic liver or renal disease
• Use of therapeutic coumadin
• Central nervous system (CNS) infiltration

Additional protocol-defined inclusion/exclusion criteria may apply.